Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Early Pregnancy Loss Treatment & Management

  • Author: Elizabeth E Puscheck, MD; Chief Editor: Richard Scott Lucidi, MD, FACOG  more...
 
Updated: Nov 15, 2015
 

Medical Care

A complete abortion usually needs no further treatment, medically or surgically. Patients do not need to remain in the hospital when a diagnosis of complete abortion is made; these patients are usually sent home. However, if there are concerns about significant blood loss, then the patient may need to stay for 24-hour observation and receive blood transfusions. If there are concerns regarding significant infection, IV antibiotic therapy may be needed for a short time until fever/symptoms resolve.

With missed, incomplete, or inevitable abortion present before 13 weeks' gestation, the standard therapy has been suction D&C. However, at least 2 randomized controlled trials show that misoprostol is an effective alternative medical therapy. In one study of incomplete abortion, the patients were randomized between oral misoprostol (600 mcg) or suction D&C, with success rates at 96.3% and 91.5%, respectively. The complication rate is low (0.9% for misoprostol).[22]

The other study was a randomized controlled trial with a 3:1 randomization to medical therapy versus D&C. It included subjects with the following diagnoses: missed abortion (with or without a fetal pole; no fetal heart motion when the fetal pole was present), incomplete abortion, or inevitable abortion. In this study, the initial dose of misoprostol was 800 mcg (4 tab 200 mcg placed vaginally), and the subject was reevaluated on day 3. If the expulsion had not occurred, then a second dose of 800 mcg of misoprostol was placed vaginally. The study showed that 71% had completed abortion after the first dose by day 3, and 84% had success with misoprostol by day 8 (95% confidence interval, 81-87%). The risks for bleeding and infection were similar to those of surgical management.[23]

Medical therapy using misoprostol is an acceptable alternative to surgical therapy for most women based upon these early data. The patient should be counseled regarding the risks and benefits of both. The advantages of medical therapy is that no surgical procedures are needed if it is successful. Passage of tissue should happen within a few days of receiving medical therapy. If it is not successful, then a surgical approach may follow. The risks for medical therapy include bleeding, infection, possible incomplete abortion, and possible failure of the medication to work. The advantage of a suction D&C is that the procedure is scheduled and occurs at a known time. The risks of a D&C include bleeding, infection, possible perforation of the uterus (as noted in Surgical Care), and possible Asherman syndrome after the procedure.

In patients with recrruent pregnancy loss (≥2 miscarriages) and cellur immunity anomalies (eg, elevated natural killer cell levels or cytotoxicity and increased T-helper cell 1  (Th1) to Th2 ratio), intravenous immunoglobulin (IVIG) may improve pregnancy outcomes.[24]

In a murine model, combined therapy with sildenafil and heparin prevented fetal loss, which may have implications in the management of women with impending pregnancy loss or for prevention in women with a history of recurrent miscarriages.[25]

Large blood loss

In the situation in which a considerable amount of blood loss has occurred, aggressive hydration, iron therapy or transfusions may be indicated.

Misdiagnosis

If the diagnosis in not correct, the patient is likely to continue to bleed and cramp for an incomplete or inevitable abortion. In these situations, a suction D&C is indicated. If the patient has any signs of infection, start antibiotics prior to the D&C, if possible, without significantly delaying the suction D&C.

Ectopic pregnancy

An ectopic pregnancy may be treated medically or surgically, depending on the clinical scenario. Treatment guidelines for ectopic pregnancy are available from the American College of Obstetricians and Gynecologists.[26] (See Ectopic Pregnancy for further information.)

Note the following:

  • Medical therapy consists of methotrexate, which is usually administered in a dose of 50 mg/m 2. The maximum dose is 100 mg. The effectiveness of medical therapy depends on only applying it to patients who are appropriate candidates based on gestational age, hCG level, ectopic size, patient reliability and compliance, proximity to the office or hospital, and health.
  • Prior to administering the methotrexate, renal and liver function tests are measured and results should be normal. A CBC is warranted, and, if significant anemia exists, then medical therapy is not warranted.
  • The absolute limits for gestational age, hCG level, ectopic size, and the presence or absence of an embryonic heartbeat are debated in the literature. Despite the debate, the factors that decrease the likelihood of success are older gestational age, higher hCG, larger ectopic size, and the presence of a fetal heartbeat.
  • The author likes to use a rule of 3's because it is easy to remember. A patient who is less than 3 weeks from expected menses (7 wk from last menstrual period [LMP]), has an hCG level less than 3000 mIU/mL, and has an ectopic size less than 3 cm has a 95% chance of success with methotrexate. An increase beyond these parameters for gestational age, hCG level, or ectopic size, or presence of a fetal heart motion on ultrasound significantly decreases the success of this medical approach. The patient should not have pelvic pain and should have only minimal vaginal bleeding for medical therapy to be considered.
  • On the day of methotrexate injection and on days 4 and 7 after the injection, the hCG level is monitored. A 15% drop in the hCG level is expected between day 4 and day 7. [26] From day 1 to day 4, a rise in the hCG level may occur. If a 15% or more drop in the hCG level occurs from day 4 to day 7, then the patient is monitored with weekly hCG levels until the level is less than 5 mIU/mL.
  • Patients may have some cramping or discomfort on the side of the ectopic pregnancy as the hCG declines, but these symptoms should be mild. Typically, patients do not experience bleeding until the hCG level is low.
  • The authors encourage increased fluid intake to avoid some of the adverse effects of methotrexate (eg, mouth sores, renal impairment). However, this dose of methotrexate is much smaller than that used to treat trophoblastic disease, and most patients have very little problems with taking it.

Plateau or rising hCG after methotrexate therapy

After methotrexate therapy for an ectopic pregnancy, any plateau or rising of hCG requires evaluation. In some situations, considering a second dose of methotrexate is possible. However, surgery should be considered as well.

Potential ectopic rupture

Any symptoms suggesting ectopic rupture (eg, acute pain, rebound tenderness) should immediately direct the physician to the operating room. NOoe the following:

  • Laparoscopy can still be considered if the patient is stable.
  • A linear salpingostomy with excision of the ectopic pregnancy or partial salpingectomy are the possible procedures.
  • If the patient is unstable, the same procedures are performed using a laparotomy.

Complete abortion

For a complete abortion, the medical care is to treat any remaining anemia and to evaluate the blood type and treat the patient with RhoGAM when indicated.

Prehospital care

Monitor vital signs and provide fluid resuscitation if the patient is hemodynamically stable.

Emergency department care

If patients know what to expect, most with complete abortions are not treated in the emergency department. Only those with significant blood loss go to the emergency department.

Patients with threatened, inevitable, incomplete, and ectopic pregnancies may go to the emergency department. Patients with threatened abortions need an ultrasonographic evaluation to confirm the diagnosis and for reassurance.

A possible treatment for threatened miscarriage is the use of progestogen. In 4 randomized studies involving 421 women that compared the use of progestogen in the treatment of threatened miscarriage with either placebo or no treatment, limited evidence suggests that the use of progestogen can reduce the rate of spontaneous miscarriage. Treatment with progestogens did not increase the occurrence of congenital abnormalities in the newborns, and the women did not have any significant difference in incidence of pregnancy-induced hypertension nor antepartum hemorrhage. Further larger studies are warranted for stronger conclusions.[27]

Abortion, Inevitable, Abortion, Incomplete, and Ectopic Pregnancy are discussed above and in separate articles.

Consultations

Consult an obstetrician/gynecologist any time uncertainty about the diagnosis exists and to administer treatment.

Diet and activity

The patient's diet should be regular if the diagnosis truly is a complete abortion. If any uncertainty about the diagnosis exists, restrict oral intake until certain that surgical treatment is not necessary.

The patient should rest for a few days to 2 weeks for a complete abortion. The rest schedule needs to be adjusted if one of the other diagnoses is correct.

Next

Surgical Care

Note the following:

  • No surgical care is used for complete abortion.
  • Inevitable and incomplete abortions are typically treated surgically with suction D&C.
  • A septic abortion requires broad spectrum antibiotic therapy prior to a suction D&C, if possible without delaying the D&C.
  • If a boggy uterus is noted with active bleeding during a D&C, then methylergonovine maleate (Methergine) (0.2 mg IM) may be given to contract the uterus. This will also decrease the likelihood that clots will be retained in the uterus.
  • An ectopic pregnancy may be treated medically for the appropriate candidates. The rest require surgery. Surgery for an ectopic pregnancy may consist of either linear salpingostomy or partial or complete salpingectomy via laparoscopy or laparotomy. Although most ectopic pregnancies occur in the fallopian tube, rarely they are located in the ovary and the ovary may need to be removed. An ectopic pregnancy may be found in the abdomen after a tubal abortion has occurred. In this case, the ectopic gestation is removed. If it is adherent to the bowel, then the ectopic gestation is removed as much as possible and follow-up treatment with methotrexate is warranted. In this latter case, the hCG levels need to be monitored until they are less than 5 mIU/mL. For more information, see Medscape Reference article Ectopic Pregnancy.
  • Whenever the diagnosis is uncertain, a diagnostic suction D&C with a diagnostic laparoscopy may be appropriate.
Previous
 
 
Contributor Information and Disclosures
Author

Elizabeth E Puscheck, MD Professor, Department of Obstetrics and Gynecology, Wayne State University School of Medicine; In Vitro Fertilization Director, Gynecologic Ultrasound Director, Clinical Endocrine Laboratory Consultant, Department of Obstetrics and Gynecology, University Women's Care

Elizabeth E Puscheck, MD is a member of the following medical societies: American Institute of Ultrasound in Medicine, International Society for Clinical Densitometry, Society for Assisted Reproductive Technology, Society of Reproductive Surgeons, Society for Reproductive Endocrinology and Infertility, American College of Obstetricians and Gynecologists, American Society for Reproductive Medicine, Association of Professors of Gynecology and Obstetrics, Endocrine Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Richard S Legro, MD Professor, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology, Pennsylvania State University College of Medicine; Consulting Staff, Milton S Hershey Medical Center

Richard S Legro, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, Society of Reproductive Surgeons, American Society for Reproductive Medicine, Endocrine Society, Phi Beta Kappa

Disclosure: Received honoraria from Korea National Institute of Health and National Institute of Health (Bethesda, MD) for speaking and teaching; Received honoraria from Greater Toronto Area Reproductive Medicine Society (Toronto, ON, CA) for speaking and teaching; Received honoraria from American College of Obstetrics and Gynecologists (Washington, DC) for speaking and teaching; Received honoraria from National Institute of Child Health and Human Development Pediatric and Adolescent Gynecology Research Thi.

Chief Editor

Richard Scott Lucidi, MD, FACOG Associate Professor of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Virginia Commonwealth University School of Medicine

Richard Scott Lucidi, MD, FACOG is a member of the following medical societies: American College of Obstetricians and Gynecologists, American Society for Reproductive Medicine

Disclosure: Nothing to disclose.

Additional Contributors

Suzanne R Trupin, MD, FACOG Clinical Professor, Department of Obstetrics and Gynecology, University of Illinois College of Medicine at Urbana-Champaign; CEO and Owner, Women's Health Practice; CEO and Owner, Hada Cosmetic Medicine and Midwest Surgical Center

Suzanne R Trupin, MD, FACOG is a member of the following medical societies: American College of Obstetricians and Gynecologists, American Institute of Ultrasound in Medicine, International Society for Clinical Densitometry, AAGL, North American Menopause Society, American Medical Association, Association of Reproductive Health Professionals

Disclosure: Nothing to disclose.

Acknowledgements

The authors and editors of Medscape Drugs & Diseases gratefully acknowledge the contributions of previous author Archana Pradhan, MD, MPH, to the development and writing of this article.

References
  1. Cengiz H, Dagdeviren H, Kanawati A, et al. Ischemia-modified albumin as an oxidative stress biomarker in early pregnancy loss. J Matern Fetal Neonatal Med. 2015 Sep 18. 1-4. [Medline].

  2. Barnhart KT, Katz I, Hummel A, Gracia CR. Presumed diagnosis of ectopic pregnancy. Obstet Gynecol. 2002 Sep. 100(3):505-10. [Medline].

  3. Condous G, Kirk E, Lu C, et al. There is no role for uterine curettage in the contemporary diagnostic workup of women with a pregnancy of unknown location. Hum Reprod. 2006 Oct. 21(10):2706-10. [Medline].

  4. Calleja-Agius J, Jauniaux E, Pizzey AR, Muttukrishna S. Investigation of systemic inflammatory response in first trimester pregnancy failure. Hum Reprod. 2011 Nov 29. [Medline].

  5. Nelson DB, Hanlon AL, Wu G, Liu C, Fredricks DN. First trimester levels of BV-associated bacteria and risk of miscarriage among women early in pregnancy. Matern Child Health J. 2015 Dec. 19 (12):2682-7. [Medline].

  6. Giakoumelou S, Wheelhouse N, Cuschieri K, Entrican G, Howie SE, Horne AW. The role of infection in miscarriage. Hum Reprod Update. 2015 Sep 19. [Medline].

  7. Thangaratinam S, Tan A, Knox E, et al. Association between thyroid autoantibodies and miscarriage and preterm birth: meta-analysis of evidence. BMJ. 2011 May 9. 342:d2616. [Medline]. [Full Text].

  8. Arck PC, Rucke M, Rose M, et al. Early risk factors for miscarriage: a prospective cohort study in pregnant women. Reprod Biomed Online. 2008 Jul. 17(1):101-13. [Medline].

  9. Maconochie N, Doyle P, Prior S, Simmons R. Risk factors for first trimester miscarriage--results from a UK-population-based case-control study. BJOG. 2007 Feb. 114(2):170-86. [Medline].

  10. Gracia CR, Sammel MD, Chittams J, Hummel AC, Shaunik A, Barnhart KT. Risk factors for spontaneous abortion in early symptomatic first-trimester pregnancies. Obstet Gynecol. 2005 Nov. 106(5 Pt 1):993-9. [Medline].

  11. Nakhai-Pour HR, Perrine B, Sheehy O, Berard A. Use of nonaspirin nonsteroidal anti-inflammatory drugs during pregnancy and the risk of spontaneous abortion. CMAJ. September 6, 2011. [Full Text].

  12. Hahn KA, Hatch EE, Rothman KJ, et al. Body Size and Risk of Spontaneous Abortion among Danish Pregnancy Planners. Paediatr Perinat Epidemiol. 2014 Sep. 28(5):412-23. [Medline].

  13. Clifford K, Rai R, Regan L. Future pregnancy outcome in unexplained recurrent first trimester miscarriage. Hum Reprod. 1997 Feb. 12(2):387-9. [Medline].

  14. Liddell HS, Pattison NS, Zanderigo A. Recurrent miscarriage--outcome after supportive care in early pregnancy. Aust N Z J Obstet Gynaecol. 1991 Nov. 31(4):320-2. [Medline].

  15. Stray-Pedersen B, Stray-Pedersen S. Etiologic factors and subsequent reproductive performance in 195 couples with a prior history of habitual abortion. Am J Obstet Gynecol. 1984 Jan 15. 148(2):140-6. [Medline].

  16. Chang J, Elam-Evans LD, Berg CJ, et al. Pregnancy-related mortality surveillance--United States, 1991--1999. MMWR Surveill Summ. 2003 Feb 21. 52(2):1-8. [Medline].

  17. O’Riordan M. Pregnancy loss associated with a later risk of atherosclerosis. March 29, 2013. Available at http://www.medscape.com/viewarticle/781681.

  18. Ranthe MF, Andersen EA, Wohlfarht J, Bundgaard H, Melbye M, Boyd HA. Pregnancy Loss and Later Risk of Atherosclerotic Disease. Circulation. 2013 Mar 27. [Medline].

  19. Practice Committee of American Society for Reproductive Medicine. Medical treatment of ectopic pregnancy. Fertil Steril. 2008 Nov. 90(5 Suppl):S206-12. [Medline].

  20. Lewis R. First Do No Harm: Guidelines Define a Nonviable Pregnancy. Medscape Medical News. Available at http://www.medscape.com/viewarticle/812346. Accessed: October 15, 2013.

  21. Doubilet PM, Benson CB, Bourne T, Blaivas M. Diagnostic Criteria for Nonviable Pregnancy Early in the First Trimester. N Engl J Med. 2013 Oct 10. 369(15):1443-1451. [Medline].

  22. Weeks A, Alia G, Blum J, et al. A randomized trial of misoprostol compared with manual vacuum aspiration for incomplete abortion. Obstet Gynecol. 2005 Sep. 106(3):540-7. [Medline].

  23. Zhang J, Gilles JM, Barnhart K, Creinin MD, Westhoff C, Frederick MM. A comparison of medical management with misoprostol and surgical management for early pregnancy failure. N Engl J Med. 2005 Aug 25. 353(8):761-9. [Medline].

  24. Lee SK, Kim JY, Han AR, et al. Intravenous immunoglobulin G improves pregnancy outcome in women with recurrent pregnancy losses with cellular immune abnormalities. Am J Reprod Immunol. 2015 Oct 29. [Medline].

  25. Luna RL, Nunes AK, Oliveira AG, et al. Sildenafil (Viagra) blocks inflammatory injury in LPS-induced mouse abortion: A potential prophylactic treatment against acute pregnancy loss?. Placenta. 2015 Oct. 36 (10):1122-9. [Medline].

  26. [Guideline] American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 94: Medical management of ectopic pregnancy. Obstet Gynecol. 2008 Jun. 111(6):1479-85. [Medline]. [Full Text].

  27. Wahabi HA, Fayed AA, Esmaeil SA, Al Zeidan RA. Progestogen for treating threatened miscarriage. Cochrane Database Syst Rev. 2011 Dec 7. 12:CD005943. [Medline].

  28. Boyle FM, Mutch AJ, Barber EA, Carroll C, Dean JH. Supporting parents following pregnancy loss: a cross-sectional study of telephone peer supporters. BMC Pregnancy Childbirth. 2015 Nov 9. 15:291. [Medline].

  29. [Guideline] ACOG practice bulletin. ACOG practice bulletin. Medical management of tubal pregnancy. Number 3, December 1998. Clinical management guidelines for obstetrician-gynecologists. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet. 1999 Apr. 65(1):97-103. [Medline].

  30. Chipchase J, James D. Randomised trial of expectant versus surgical management of spontaneous miscarriage. Br J Obstet Gynaecol. 1997 Jul. 104(7):840-1. [Medline].

  31. Chung TK, Cheung LP, Sahota DS, Haines CJ, Chang AM. Spontaneous abortion: short-term complications following either conservative or surgical management. Aust N Z J Obstet Gynaecol. 1998 Feb. 38(1):61-4. [Medline].

  32. Creinin MD, Schwartz JL, Guido RS, Pymar HC. Early pregnancy failure--current management concepts. Obstet Gynecol Surv. 2001 Feb. 56(2):105-13. [Medline].

  33. Geyman JP, Oliver LM, Sullivan SD. Expectant, medical, or surgical treatment of spontaneous abortion in first trimester of pregnancy? A pooled quantitative literature evaluation. J Am Board Fam Pract. 1999 Jan-Feb. 12(1):55-64. [Medline].

  34. Hurd WW, Whitfield RR, Randolph JF Jr, Kercher ML. Expectant management versus elective curettage for the treatment of spontaneous abortion. Fertil Steril. 1997 Oct. 68(4):601-6. [Medline].

  35. Jurkovic D, Ross JA, Nicolaides KH. Expectant management of missed miscarriage. Br J Obstet Gynaecol. 1998 Jun. 105(6):670-1. [Medline].

  36. Kalousek DK. Clinical significance of morphologic and genetic examination of spontaneously aborted embryos. Am J Reprod Immunol. 1998 Feb. 39(2):108-19. [Medline].

  37. Katz VL, Lentz G, Lobo RA, Gershenson DM, eds. Comprehensive Gynecology. 5th ed. Philadelphia: Mosby Elsevier; 2007.

  38. Keith SC, London SN, Weitzman GA, O'Brien TJ, Miller MM. Serial transvaginal ultrasound scans and beta-human chorionic gonadotropin levels in early singleton and multiple pregnancies. Fertil Steril. 1993 May. 59(5):1007-10. [Medline].

  39. Nielsen S, Hahlin M. Expectant management of first-trimester spontaneous abortion. Lancet. 1995 Jan 14. 345(8942):84-6. [Medline].

  40. Scroggins KM, Smucker WD, Krishen AE. Spontaneous pregnancy loss: evaluation, management, and follow-up counseling. Prim Care. 2000 Mar. 27(1):153-67. [Medline].

  41. van Veen TR, Haeri S, Baker AM. Teen pregnancy: are pregnancies following an elective termination associated with increased risk for adverse perinatal outcomes?. J Pediatr Adolesc Gynecol. 2015 Dec. 28 (6):530-2. [Medline].

  42. Marko EK, Buery-Joyner SD, Sheridan MJ, Nieves K, Khoury AN, Dalrymple JL. Structured teaching of early pregnancy loss counseling. Obstet Gynecol. 2015 Oct. 126 suppl 4:1S-6S. [Medline].

 
Previous
Next
 
Second transvaginal sonogram obtained 1 week after the initial study fails to demonstrate fetal development. This confirms the diagnosis of an embryonic pregnancy.
1a Video courtesy; Armando Hernandez
1b Video courtesy; Armando Hernandez
1c Video courtesy; Armando Hernandez
1d Video courtesy; Armando Hernandez
1e Video courtesy; Armando Hernandez
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.